NASDAQ:GLSI Greenwich LifeSciences (GLSI) Stock Price, News & Analysis $14.88 -0.01 (-0.07%) (As of 05:26 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Greenwich LifeSciences alerts: Email Address About Greenwich LifeSciences Stock (NASDAQ:GLSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Greenwich LifeSciences alerts:Sign Up Key Stats Today's Range$14.50▼$15.2850-Day Range$12.99▼$16.6252-Week Range$7.58▼$21.44Volume88,930 shsAverage Volume42,953 shsMarket Capitalization$191.65 millionP/E RatioN/ADividend YieldN/APrice Target$38.00Consensus RatingBuy Company OverviewGreenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Read More… Forget Trump and Kamala (Ad)Forget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.Download my Dividend Calendar here Greenwich LifeSciences Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 51st PercentileGreenwich LifeSciences scored higher than 51% of companies evaluated by MarketBeat, and ranked 581st out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGreenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGreenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.Read more about Greenwich LifeSciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Greenwich LifeSciences are expected to decrease in the coming year, from ($0.81) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Greenwich LifeSciences is -20.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Greenwich LifeSciences is -20.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGreenwich LifeSciences has a P/B Ratio of 28.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Greenwich LifeSciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.87% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 3.30%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGreenwich LifeSciences does not currently pay a dividend.Dividend GrowthGreenwich LifeSciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.87% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 3.30%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News Sentiment1.09 News SentimentGreenwich LifeSciences has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Greenwich LifeSciences this week, compared to 1 article on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $138,555.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.86% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.16% of the stock of Greenwich LifeSciences is held by institutions.Read more about Greenwich LifeSciences' insider trading history. Receive GLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address GLSI Stock News HeadlinesGreenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Buys 800 SharesSeptember 17 at 5:09 AM | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Buys 800 Shares of StockSeptember 17 at 5:11 AM | americanbankingnews.comAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowSeptember 20, 2024 | Brownstone Research (Ad)Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders seem bullish, own 55% and have been buying more recentlySeptember 12, 2024 | finance.yahoo.comInsider Stock Buying Reaches US$3.36m On Greenwich LifeSciencesAugust 17, 2024 | uk.finance.yahoo.comGreenwich Lifesciences Inc (GLSI)August 4, 2024 | investing.comGreenwich LifeSciences Provides Update on Expansion of Flamingo-01 into SpainAugust 1, 2024 | globenewswire.comGreenwich LifeSciences Set to Join Russell 2000 Index AgainJune 26, 2024 | globenewswire.comSee More Headlines GLSI Stock Analysis - Frequently Asked Questions How have GLSI shares performed this year? Greenwich LifeSciences' stock was trading at $10.52 at the beginning of the year. Since then, GLSI stock has increased by 41.4% and is now trading at $14.88. View the best growth stocks for 2024 here. How were Greenwich LifeSciences' earnings last quarter? Greenwich LifeSciences, Inc. (NASDAQ:GLSI) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.20) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.20). When did Greenwich LifeSciences IPO? Greenwich LifeSciences (GLSI) raised $7 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 1,300,000 shares at a price of $5.75 per share. Aegis Capital acted as the underwriter for the IPO. Who are Greenwich LifeSciences' major shareholders? Greenwich LifeSciences' top institutional investors include Bank of New York Mellon Corp (0.12%) and Rhumbline Advisers (0.05%). Insiders that own company stock include Snehal Patel, Jaye Thompson, Frank Joseph Daugherty, David Mcwilliams and Kenneth Hallock. View institutional ownership trends. How do I buy shares of Greenwich LifeSciences? Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/14/2024Today9/20/2024Next Earnings (Estimated)10/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLSI CUSIPN/A CIK1799788 Webwww.greenwichlifesciences.com Phone832-819-3232FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$38.00 High Stock Price Target$38.00 Low Stock Price Target$38.00 Potential Upside/Downside+158.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-153.96% Return on Assets-141.52% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book28.33Miscellaneous Outstanding Shares12,880,000Free Float6,072,000Market Cap$189.72 million OptionableNot Optionable Beta1.61 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:GLSI) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.